Abstract
The aim of the study was to study the efficacy and tolerability of the sequential use of the fixed combination of clindamycin + BPO in various clinical situations in real practice. Under our supervision there were 32 patients with mild-to-moderate and severe acne of papulo-pustular acne. Among them, 21 (65.6 %) female patients and 11 (34.4 %) male patients. The patients were divided into two groups: group 1 (teenage acne) of 17 people, group 2 (adult acne) of 15 people. The therapy algorithm included the use of a fixed combination of clindamycin + BPO (Zerkalin Intensive) for 4–5 weeks with a sequential transition to the use of a topical agent with adapalene for 6 months. All patients were prescribed specialized dermatocosmetics on an ongoing basis. As a result of therapy, after a week, there was a significantly significant change in all clinical symptoms of acne. So VAS (comedones) at the end of therapy decreased by 88.9 % (p < 0.01) and by 90.5 % (p < 0.01) in groups 1 and 2, respectively. Similar dynamics was noted in relation to inflammatory elements (papules, pustules). VAS (papules) in groups 1 and 2 decreased by 85.4 % (p < 0.01) and by 88.1 % (p < 0.01), VAS (pustules) – by 100 %. Thus, the use of a fixed combination of clindamycin + BPO causes a high therapeutic effect in relation to all clinical symptoms of acne.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
